RA Capital Management is a Boston-based investment advisor founded in 2004, specializing in the life sciences and healthcare sectors. The firm focuses on early-stage companies developing innovative technologies, products, and services in drug development, medical devices, diagnostics, and research tools. With a team of professionals trained in biology, chemistry, and medicine, RA Capital Management leverages its extensive industry and business development experience to identify and invest in promising healthcare ventures. As a Registered Investment Adviser, the firm employs a strategic approach that includes both venture capital investments and a hedge fund strategy, targeting opportunities primarily in the United States and Europe.

OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.

The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.

Perceptive Advisors, established in 1999, is a New York-based investment management firm specializing in the life sciences sector. It invests in both private and public biotechnology, pharmaceutical, medical device, diagnostics, and health services companies across their lifecycle, from seed and early-stage ventures to public equities. The firm employs a long/short equity strategy and conducts in-house research to identify promising opportunities. Perceptive Advisors also offers customized debt financing solutions through its Perceptive Credit Opportunities Fund.

SOSV, established in 1995 and headquartered in Princeton, New Jersey, is a global venture capital firm specializing in early-stage investments. It focuses on deep tech innovations in the health and environmental sectors, supporting founders with breakthrough technologies through its HAX and IndieBio startup development programs. SOSV provides resources, facilities, and lab equipment to accelerate product development and scale, with a track record of helping its portfolio companies secure subsequent funding rounds led by top-tier investors.

Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.

Samsara BioCapital LLC is a principal investment firm established in 2016 and located in Palo Alto, California. The company specializes in providing investment advisory services aimed at supporting biotechnology firms and entrepreneurs in transforming their ideas into successful ventures. It focuses on sectors such as healthcare, life sciences, oncology, and digital health, emphasizing innovation in the development of new therapies. Samsara BioCapital actively seeks to partner with ambitious and visionary companies, fostering collaboration to advance significant advancements in biotechnology.

Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.

The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.

Janus Henderson Investors is a global asset management firm headquartered in London, United Kingdom, with a history dating back to 1934. The company specializes in delivering investment performance and services to a diverse clientele, including institutional, retail, and high-net-worth clients. It connects these clients with investment professionals who have expertise across a wide range of asset classes, such as equities, fixed income, real estate, and alternative investments. Janus Henderson Investors aims to provide tailored investment solutions that meet the unique needs of its clients while fostering long-term financial growth.

Novo Holdings, established in 1999, is a Danish asset management firm based in Copenhagen. It serves as the investment arm of the Novo Nordisk Foundation, managing its assets and wealth. The company's primary focus is the life science sector, with a diversified portfolio comprising equities, bonds, real estate, infrastructure, and private investments. Novo Holdings maintains a significant influence on Novo Nordisk A/S and Novozymes A/S, ensuring these companies align with the Novo Group's visions and values. It also invests in early and growth-stage life science companies through its venture capital arm, Novo Ventures, which targets investments ranging from USD 5 million to USD 30 million.

Innovate UK is a non-departmental public body established in 2007 and based in Swindon, United Kingdom. Funded by a government grant, it supports innovation in science and technology by providing funding services to businesses across various sectors and regions. The organization aims to drive productivity and economic growth by facilitating advancements that contribute to the UK’s economic landscape. In addition to funding, Innovate UK offers a range of services and information related to business and economic development, thereby fostering a supportive environment for innovation.

Biotechnology Value Fund is a private investment partnership based in San Francisco, focusing on fundamentally-driven public biotechnology investments. Established in 1993, the fund aims to create concentrated, long-term investments in small-cap biotechnology firms. It emphasizes rigorous due diligence and continuous monitoring of its portfolio to ensure sustainable growth. Furthermore, Biotechnology Value Fund is dedicated to collaborating with its portfolio companies, fostering partnerships that support mutual success in the biotechnology sector.

Venrock, established in 1969, is a venture capital firm headquartered in Palo Alto, California, with additional offices in New York. It specializes in seed and early-stage investments, primarily in technology and healthcare sectors. The firm partners with entrepreneurs to build successful, enduring companies, with a notable track record including Apple, Athenahealth, and Gilead Sciences. Venrock also manages dedicated funds for healthcare investments, such as Venrock Healthcare Capital Partners, focusing on both private and public biotechnology companies.

New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, headquartered in Menlo Park, California, with additional offices in the U.S., India, and China. NEA specializes in investing in technology and healthcare sectors, with a focus on enterprise, consumer, fintech, life sciences, and digital health companies. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. NEA invests globally, with a significant presence in Asia, including China and India, as well as the United States. The firm typically invests between $0.05 million and $20 million per deal.

ARCH Venture Partners, established in 1986, is a U.S.-based venture capital firm with a global scope. It specializes in investing in technology companies, with a primary focus on life sciences. ARCH invests conservatively in seed rounds to mitigate risk, and then leads or co-leads subsequent financing rounds until liquidity. The firm is known for its success in commercializing technologies from academic research institutions and national laboratories, often investing in companies co-founded by scientists and entrepreneurs. ARCH has raised over $3 billion across ten funds and has invested in over 150 companies, typically committing between $50,000 and $150 million per company. It seeks a seat on the Board of Directors and maintains a presence in underserved geographic markets. ARCH's investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

Sanofi Oncology, a division of global healthcare company Sanofi, focuses on developing and delivering innovative treatments for various types of cancer. With a rich heritage in oncology, Sanofi Oncology leverages its extensive knowledge base to research and treat cancer from multiple angles, addressing diverse patient needs and disease stages. The company's portfolio includes therapies for rare diseases, immunology, and cardiovascular conditions, among others. Sanofi's commitment to patients drives its strategy to create long-term value through innovative treatments, from research and development to manufacturing and marketing.

Redmile Group, established in 2007, is a private equity firm headquartered in San Francisco with an additional office in New York. The company specializes in healthcare investments, focusing on venture capital opportunities within the sector.

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. It specializes in seed, early-stage, and growth capital investments primarily within the healthcare sector, with a particular emphasis on biopharma, diagnostics, life sciences, agrifood technology, and technology sectors. The firm is recognized for its strategic approach, providing long-term investment capital to innovative companies that are developing transformative technologies and therapies aimed at improving human health. As a subsidiary of Alexandria Real Estate Equities, Alexandria Venture Investments leverages its deep industry expertise, extensive relationships with investors, and a world-class scientific advisory network to support and fund promising startups and growth-oriented companies in disruptive life science and technology.

Vivo Capital, established in 1996, is a global investment firm headquartered in Palo Alto, California, with a presence in Asia. It manages approximately $5.8 billion in assets, invested across over 290 public and private healthcare companies worldwide. The firm's 50-strong team comprises professionals with diverse backgrounds, including physicians, scientists, entrepreneurs, and industry experts. Vivo Capital operates a multi-fund platform, covering growth equity, private equity, venture capital, and public equity, with a broad focus on healthcare sectors such as biotechnology, pharmaceuticals, medical devices, and healthcare services. It primarily invests in the largest healthcare markets.

Versant Ventures, established in 1999, is a global healthcare investment firm headquartered in San Francisco, California. With over $2.3 billion under management and offices in North America and Europe, the firm invests across the healthcare sector, with a focus on discovering and developing novel therapeutics. Versant's team, comprising deep investment, operating, and scientific expertise, takes a hands-on approach to company building. Since inception, over 65 Versant companies have achieved successful acquisitions or IPOs.

The National Science Foundation (NSF) is an independent federal agency established in 1950 and based in Alexandria, Virginia. It is dedicated to supporting research and education in science and engineering across a wide range of disciplines. The NSF provides significant non-dilutive funding, up to $1.5 million, to startups and small businesses through its America's Seed Fund initiative, which is part of the Small Business Innovation Research (SBIR) program mandated by Congress. With an operating budget of approximately $7.8 billion, the NSF is committed to advancing fundamental research and education, thus fostering innovation and technological development in the United States.

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing evolving patient needs worldwide. It operates through several divisions: Novartis Pharmaceuticals for innovative medicines, Sandoz for generics and biosimilars, and Alcon for eye care devices. The company focuses on key therapeutic areas such as oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic diseases. Novartis also invests in early-stage life sciences and biotechnology companies through its venture capital arm, Novartis Venture Fund, seeking innovative therapeutics, medical devices, diagnostics, and drug delivery systems. Additionally, Novartis Animal Health develops products for pets, farm animals, and farmed fish, contributing to animal health and welfare. The company's research and development efforts are supported by the Genomics Institute of the Novartis Research Foundation, which bridges basic science and preclinical drug discovery.

Cormorant Asset Management, established in 2013 and headquartered in Boston, Massachusetts, is an employee-owned hedge fund sponsor. It offers services to pooled investment vehicles, specializing in investments across both public and private markets within the biotechnology and life sciences sectors.

Surveyor Capital is a fundamental equities business that operates sector-aligned investment teams focusing on market neutral strategies. The company aims to generate alpha by gaining a deep understanding of each company's strategy, management teams, performance drivers, and industry trends over the medium and long term. With a focus on fundamental analysis, Surveyor Capital strives to achieve success through a comprehensive approach to investment in the equities market.

Google.org is a philanthropic arm of Google, a multinational technology company. It funds and supports nonprofits globally, providing them with funding, tools, and volunteers. Google.org has committed approximately $100 million annually to these efforts, aiming to extend the reach of innovative nonprofits and create lasting global impact.

Deep Track Capital is a private equity investment firm established in 2020 and based in Greenwich, Connecticut. It specializes in the life sciences and biotechnology sectors, focusing on forming partnerships with management teams of innovative public and pre-IPO biotechnology companies. The firm aims to leverage its expertise and extensive network to provide value beyond capital, actively participating in transactions and often leading investment rounds while collaborating with other qualified investors. As a Registered Investment Adviser, Deep Track Capital is dedicated to fostering growth and innovation within the life sciences industry.

RTW Investments, LP is an employee-owned hedge fund manager based in New York, with additional offices in London and Shanghai. Established in 2009, the firm specializes in investments within the healthcare sector, focusing on life sciences, big data, and digital health. RTW Investments engages in a comprehensive investment strategy that spans the entire lifecycle of healthcare companies, including company creation, early-stage venture capital, alternative financing, and public company investments. The firm conducts thorough in-house fundamental research to inform its investment decisions, managing both pooled investment vehicles and separate client-focused equity and fixed income portfolios.

Pfizer, established in 1849, is a leading global pharmaceutical company headquartered in the United States. Its core business involves the discovery, development, manufacture, and sale of prescription medicines, vaccines, and health care products. Pfizer's extensive portfolio spans various therapeutic areas, focusing on wellness and prevention, as well as treatments and cures for numerous diseases. Notable products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. With approximately 50% of its sales coming from international markets, including significant contributions from emerging markets, Pfizer's global presence is substantial. The company is committed to providing access to safe, effective, and affordable medicines, driven by its purpose to improve patient outcomes and enhance overall health. Pfizer Venture Investments, its corporate venture capital arm, invests in emerging companies developing transformative medicines and technologies to further strengthen its pipeline. Additionally, the Pfizer Foundation, an independent non-profit, supports global health strategies and community involvement through funding and resources.

Deerfield Management, established in 1994 and headquartered in New York, is a healthcare-focused investment management firm. It provides long-term structured investments in both public and private healthcare companies, spanning life science, medical device, diagnostic, digital health, and health service industries. The firm also offers information and investment services to foster a healthcare ecosystem.

Bain Capital, established in 1984, is a global multi-asset alternative investment firm with over $100 billion in assets under management. Headquartered in Boston, Massachusetts, the firm operates through several business units: Private Equity, Public Equity, Credit, and Venture Capital. Bain Capital Private Equity invests in various sectors, including consumer, healthcare, industrials, and technology, across North America, Europe, and Asia. Bain Capital Ventures, the venture capital arm, focuses on seed to growth-stage investments in enterprise software, infrastructure software, and industries being transformed by data. Bain Capital Life Sciences, a dedicated life sciences investment platform, invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Bain Capital Double Impact, the firm's impact investing arm, builds great companies that deliver both competitive financial returns and meaningful, measurable social and environmental good.

Sofinnova Partners, established in 1972 and headquartered in Paris, is a leading venture capital firm focused on the life sciences sector. It manages over €2 billion, investing from seed to later-stage in biopharmaceuticals, medical devices, and industrial biotechnology. The firm proactively sources deals, often leading financings and actively supporting portfolio companies until exit. Sofinnova Partners invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations, playing a significant role in developing transformative innovations that can positively impact the future.

Rock Springs Capital is an investment company based in Baltimore, Maryland, established in 2013. It specializes in the healthcare and biotechnology sectors, offering advisory services that focus on managing security portfolios and providing portfolio management solutions for businesses and institutional clients. The firm aims to assist clients in optimizing their investment strategies and achieving their financial objectives through its comprehensive management services.

IndieBio, established in 2014, is a San Francisco-based accelerator firm specializing in Synthetic Biology. It runs intensive four-month programs for early-stage companies and teams with innovative biological concepts. IndieBio invests in seed and early-stage startups globally, focusing on those that use biology as their core technology to solve real-world problems. The firm typically invests $250k, with an initial cash investment of $50k in exchange for an 8% equity stake. It prefers teams with at least two co-founders. IndieBio was the world's first accelerator dedicated to biology-based startups, aiming to address global challenges through innovative biotechnology.

Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in promising life science companies that exhibit strong management teams and innovative technologies or business models. While its primary investment strategy targets opportunities in China, Lilly Asia Ventures is also open to exploring prospects in other regions of East and South Asia. The firm invests across various stages, including seed, early, and later stages, with particular interest in sectors such as healthcare, life sciences, oncology, manufacturing, and technology-based industries. Through its investments, Lilly Asia Ventures aims to foster the development of innovative solutions that contribute to improved health and quality of life.

Foresite Capital, established in 2011, is a San Francisco-based healthcare and life sciences investment firm with approximately $2 billion under management. It takes a data-driven, collaborative approach to investing, providing not just capital but also a multidisciplinary team of experts to support its portfolio companies. Foresite focuses on growth equity investments across the U.S. healthcare sector, with a particular interest in startups that leverage biology, big data, and technology to improve healthcare outcomes. Its portfolio includes companies like 10x Genomics, Relay Therapeutics, and Element Biosciences. The firm aims to address areas of great unmet clinical need and supports promising healthcare and life sciences businesses at all stages of their development.

Polaris Partners, established in 1996 and headquartered in Boston, Massachusetts, is a venture capital firm focusing on healthcare, life sciences, and biotechnology sectors. The firm invests across various stages, from early-stage companies to growth equity, partnering with repeat entrepreneurs and innovators. Polaris' healthcare portfolio spans digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics, while its life sciences and biotechnology investments center around molecules, platforms, therapeutics, and genomics. With offices in Boston and San Francisco, Polaris has a 20-year history of supporting companies that improve people's lives and work.

TCG Crossover Management is a venture capital investment firm founded in 2020 and based in Palo Alto, California. The firm specializes in investing in companies within the drug discovery and medicine sectors, focusing primarily on opportunities in the United States and Europe. TCG Crossover Management is dedicated to advancing innovative healthcare solutions and supporting entrepreneurs who are committed to developing improved treatment options for patients. As a Registered Investment Adviser, the firm operates with a strong emphasis on identifying and nurturing companies that have the potential to make significant advancements in healthcare.

The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, established in 2000. It is dedicated to reducing global inequities by focusing on improving health, alleviating extreme poverty, and supporting educational initiatives. The foundation also engages in community giving within the Pacific Northwest, promoting strategies and programs that assist low-income families. With regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom, the foundation is governed by its co-founders, Bill and Melinda Gates, along with trustee Warren Buffett. Its mission encompasses a wide range of global challenges, aiming to create lasting change through targeted grant-making and programmatic efforts.

EcoR1 Capital, LLC is an employee-owned investment advisory firm based in San Francisco, California, founded in 2012. Specializing in the biotechnology sector, EcoR1 Capital focuses on identifying and evaluating innovative therapeutic solutions that can significantly enhance patient outcomes. The firm employs a long/short investment strategy primarily within the public equity markets of the United States, while also managing separate client-focused equity and fixed income portfolios. By investing in biotech companies that offer promising new treatments for untreated diseases, EcoR1 Capital aims to advance medical research and build upon the innovative contributions of its predecessors in the healthcare and life sciences fields.

Logos Capital is a biotechnology-focused investment firm based in San Francisco, California, founded in 2019. The firm specializes in identifying transformative therapies within the healthcare sector by leveraging in-house data analytics alongside scientific and clinical expertise. Logos Capital integrates knowledge from medical, scientific, and statistical fields to enhance its investment diligence, aiming to uncover compelling opportunities in the biotechnology space. The firm employs a fundamental and sector-oriented approach to equity investment, utilizing statistical modeling of clinical trials to bolster confidence in its investment positions. Through this rigorous methodology, Logos Capital seeks to deliver uncorrelated market returns while advancing innovative healthcare solutions.

F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.

Boxer Capital LLC is a venture capital firm founded in 2005 and based in San Diego, California. As a subsidiary of Tavistock Life Sciences, it specializes in investing in both private and public companies within the biotechnology and life science sectors. Boxer Capital focuses on a wide range of companies involved in the drug development lifecycle, from early stage preclinical discovery assets to late stage clinical and commercial entities. The firm aims to support the growth and advancement of biotechnology innovations through its strategic investments.

Bristol-Myers Squibb, established in 1887, is a global biopharmaceutical company. It engages in the discovery, development, licensing, manufacturing, marketing, and distribution of pharmaceutical products. The company's portfolio spans various therapeutic areas, with a significant focus on immuno-oncology. Key products include Opdivo and Yervoy for cancer indications, Eliquis for stroke prevention and blood clots, and Orencia for rheumatoid arthritis. Bristol-Myers Squibb collaborates with numerous partners to advance its pipeline and operates globally, with the U.S. contributing to approximately 70% of its total sales.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

Eli Lilly and Company is a global pharmaceutical corporation that specializes in the discovery, development, manufacturing, and distribution of medicines. Its portfolio spans various therapeutic areas, including neuroscience, cardiometabolic, cancer, and immunology. Notable products include Verzenio for cancer, Mounjaro and Jardiance for cardiometabolic conditions, and Taltz for immunology. The company operates through owned or leased facilities in over 25 countries, selling its products in approximately 135 countries worldwide. Additionally, Eli Lilly and Company Foundation, established in 1968, supports initiatives aimed at improving patient outcomes, enhancing quality of life, and promoting education, particularly in underserved communities.

CARB-X is a business that accelerates a diverse portfolio of high-quality antibacterial products towards clinical development. They leverage $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre to support their mission. With a focus on combating antimicrobial resistance, CARB-X aims to drive innovation and development in the field of antibacterial products to address global health challenges.

Sofinnova Investments, Inc. is a venture capital firm founded in 1974 and headquartered in Menlo Park, California, with additional offices in La Jolla, California, Montreal, Quebec, and Tokyo, Japan. The firm specializes in seed, early, and mid-stage investments, primarily focusing on the life sciences and information technology sectors. In life sciences, it targets clinical-stage pharmaceutical companies, biotechnology, and medical technologies addressing unmet medical needs, emphasizing areas such as oncology, neurology, and women’s health. For information technology, Sofinnova seeks product-oriented companies developing innovative software solutions and telecommunications infrastructure. The firm typically invests between $3 million and $15 million in technology companies and between $5 million and $30 million in life science companies, often requiring a board seat as part of its investment strategy. Sofinnova Investments emphasizes partnerships with entrepreneurs to help them build successful businesses and navigate key growth milestones, leveraging the expertise of its seasoned professionals.

Omega Funds, established in 2004, is a Boston-based venture capital firm specializing in early-stage investments in the life sciences, healthcare, and biotechnology sectors. The firm focuses on North America and Western Europe, with a portfolio spanning pharmaceuticals, biotechnology, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS. Omega Funds manages multiple funds, including Omega Fund V, a 2015 vintage fund targeting investments in these sectors.